Equity Overview
Price & Market Data
Price: $3.03
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $201,922,224
Volume: 0
Performance Metrics
1 Week: -2.26%
1 Month: -2.26%
3 Months: 93.61%
6 Months: 56.99%
1 Year: 114.9%
YTD: 93.61%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country: Spain
Details
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.